Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin, developing novel treatment solutions for patients with symptomatic benign prostatic hyperplasia (BPH).

BPH is a highly prevalent condition impacting an estimated 14 million men in the US and 20 million in Europe. Proverum’s solutions are designed to be safely and effectively performed in a doctor’s office during a simple procedure under local anesthesia, as an alternative to more invasive standard-of-care options. Its unique expander device made from nitinol (nickel titanium) gently reshapes the enlarged prostate, enabling more effective BPH treatment with shorter procedural times and fewer side effects for the patient.

Gilde Healthcare invested in 2022 to support the company’s clinical program and other operating activities in pursuit of regulatory approval for the ProVee system in Europe and the US.